Although actual therapy de-escalation trial to demonstrate such utility of LIMA1 biomarker is under progress to be initiated, we modeled this scenario by launching a national prospective multicenter HNSCC biomarker study across every University hospital in Finland (Turku, Helsinki, Tampere, Oulu, and Kuopio). The gene discussed is LIMA1; the disease is head and neck squamous cell carcinoma.